{"id":"W4417010329","doi":"10.1182/blood-2025-925","title":"Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Drug Research and Development","funders":"","keywords":"Tolerability; CD20; CD19; Phases of clinical research; Adverse effect; Refractory (planetary science); Cytokine release syndrome; Antigen; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002169163,0.001569313,0.001526248,0.0002734879,0.0004018603,0.001639335,0.000740124,0.001622158,0.004256852],"category_scores_gemma":[0.001358326,0.0004022094,0.001527664,0.0002674242,0.0009175617,0.0009466638,0.0004530011,0.004204096,0.001322335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008176332,"about_ca_system_score_gemma":0.001063335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008127007,"about_ca_topic_score_gemma":0.001992258,"domain_scores_codex":[0.9994569,0.0002409165,0.00002449816,0.0000783684,0.00004685905,0.000152361],"domain_scores_gemma":[0.9988893,0.000255932,0.0001346549,0.0001057763,0.00008949664,0.0005248614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4274607,0.103512,0.008813216,0.002024101,0.002908564,0.001108825,0.0008583353,0.01049661,0.1676669,0.001220678,0.03195868,0.2419715],"study_design_scores_gemma":[0.2676768,0.6597661,0.01794345,0.0001326153,0.001359059,0.001208507,0.0001817069,0.003625918,0.02720089,0.001425525,0.01938791,0.00009137608],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667928,0.005971855,0.004979369,0.002477319,0.0003517919,0.00396315,0.007711825,0.0004965721,0.007255355],"genre_scores_gemma":[0.9704179,0.002847103,0.004289208,0.003014875,0.0002028259,0.002852336,0.008881298,0.000190987,0.007303533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004256852,"threshold_uncertainty_score":0.01424056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04077552201564379,"score_gpt":0.3264877264865539,"score_spread":0.2857122044709101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}